By Denny Jacob
AngioDynamics' loss narrowed in its latest quarter as a sharp reduction in total operating expenses helped the bottom line improve.
The medical-device maker recorded a loss of $4.4 million, or 11 cents a share, for the third quarter ended Feb. 28, from about $187.7 million, or $4.67 a share, in the prior-year period.
Stripping out certain one-time items, its loss came in at 8 cents a share. Analysts polled by FactSet expected a loss of 13 cents a share.
Operating expenses in the quarter totaled $48.8 million, down from $242.4 million in the prior-year period.
Sales declined to about $72 million from $75.2 million. Analysts polled by FactSet expected $70.3 million.
Medical-technology pro-forma net sales rose 22% to $31.3 million, while medical-device pro-forma net sales edged up 0.9% to $40.7 million.
For fiscal 2025, AngioDynamics now expects adjusted sales to fall between $285 million and $288 million compared with its previous forecast in the range of $282 million and $288 million. The company expects an adjusted loss per share between 31 cents and 34 cents; its prior guidance called for an adjusted loss per share between 34 cents and 38 cents.
Shares rose 8.9% to $10.52 in premarket trading. The stock is up 59% over the last year through Tuesday's close.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 02, 2025 07:07 ET (11:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.